Table 3.

Effects of NMNAT modulators on human NMNAT1-3.

Modulator	NMNAT1	NMNAT2	NMNAT3
Gallotannin	Inhibitor (IC50 = 10 µM) [93]	Inhibitor (IC50 = 55 µM) [93]	Inhibitor (IC50 = 2 µM) [93]
Np3AD	Inhibitor (Ki is 89 µM toward NMN and 56.3 µM toward ATP) [152]	Inhibitor (Ki is 31.5 µM toward NMN and 35.9 µM   toward ATP) [152]	Inhibitor (Ki is 66.8 µM toward NMN and 40.6 µM toward ATP) [152]
Np4AD	Inhibitor (Ki is 31.1 µM toward NMN and 49.2 µM toward ATP) [152]	Inhibitor (Ki is 25.8 µM toward NMN and 24.2 µM toward ATP) [152]	Inhibitor (Ki is 73.6 µM toward NMN and 29.8 µM toward ATP) [152]
Nap4AD	Inhibitor (Ki is 67.9 µM toward NMN and 59.1 µM toward ATP) [152]	Inhibitor (Ki is 328.3 µM toward NMN and 174.5 µM toward ATP) [152]	Inhibitor (Ki is 88.3 µM toward NMN and 32.8 µM toward ATP) [152]
Na-2′-MeAD	Weak inhibitor (28% inhibition at 1 mM) [153]	Weak inhibitor (33% inhibition at 1 mM) [153]	Inhibitor (IC50 = 1120 µM) (81% inhibition at 1 mM) [153]
N-2′-MeAD	Very Weak inhibitor (9% inhibition at 1 mM) [153]	Very Weak inhibitor (9% inhibition at 1 mM) [153]	Inhibitor (IC50 = 190 µM) (65% inhibition at 1 mM) [153]
DBNQ	Inhibitor (IC50 is 0.76 µM for the forward reaction, and 0.26 µM for the reverse reaction) [155]	N/A	N/A
EGCG	Activator (1.2 fold activation at 50 µM) [93]	Activator (2.28 fold activation at 50 µM) [93]	Activator (1.42 fold activation at 50 µM) [93]

N/A; Not available.